These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32003035)

  • 41. Magnetic resonance spectroscopy of isocitrate dehydrogenase mutated gliomas: current knowledge on the neurochemical profile.
    Branzoli F; Marjańska M
    Curr Opin Neurol; 2020 Aug; 33(4):413-421. PubMed ID: 32657882
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 2-Hydroxyglutarate Detection by Short Echo Time Magnetic Resonance Spectroscopy in Routine Imaging Study of Brain Glioma at 3.0 T.
    Crisi G; Filice S; Michiara M; Crafa P; Lana S
    J Comput Assist Tomogr; 2018; 42(3):469-474. PubMed ID: 29287025
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Accuracy of 1H magnetic resonance spectroscopy for quantification of 2-hydroxyglutarate using linear combination and J-difference editing at 9.4T.
    Neuberger U; Kickingereder P; Helluy X; Fischer M; Bendszus M; Heiland S
    Z Med Phys; 2017 Dec; 27(4):300-309. PubMed ID: 28506858
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI.
    de Godoy LL; Lim KC; Rajan A; Verma G; Hanaoka M; O'Rourke DM; Lee JYK; Desai A; Chawla S; Mohan S
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
    Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
    Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
    Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
    J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry.
    Longuespée R; Wefers AK; De Vita E; Miller AK; Reuss DE; Wick W; Herold-Mende C; Kriegsmann M; Schirmacher P; von Deimling A; Pusch S
    Acta Neuropathol Commun; 2018 Mar; 6(1):21. PubMed ID: 29499756
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness.
    Tiwari V; Daoud EV; Hatanpaa KJ; Gao A; Zhang S; An Z; Ganji SK; Raisanen JM; Lewis CM; Askari P; Baxter J; Levy M; Dimitrov I; Thomas BP; Pinho MC; Madden CJ; Pan E; Patel TR; DeBerardinis RJ; Sherry AD; Mickey BE; Malloy CR; Maher EA; Choi C
    Neuro Oncol; 2020 Jul; 22(7):1018-1029. PubMed ID: 32055850
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
    Chaumeil MM; Radoul M; Najac C; Eriksson P; Viswanath P; Blough MD; Chesnelong C; Luchman HA; Cairncross JG; Ronen SM
    Neuroimage Clin; 2016; 12():180-9. PubMed ID: 27437179
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of IDH and TERTp mutation status using
    Ozturk-Isik E; Cengiz S; Ozcan A; Yakicier C; Ersen Danyeli A; Pamir MN; Özduman K; Dincer A
    J Magn Reson Imaging; 2020 Jun; 51(6):1799-1809. PubMed ID: 31664773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improving D-2-hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RF-receive/B
    Strasser B; Arango NS; Stockmann JP; Gagoski B; Thapa B; Li X; Bogner W; Moser P; Small J; Cahill DP; Batchelor TT; Dietrich J; van der Kouwe A; White J; Adalsteinsson E; Andronesi OC
    NMR Biomed; 2022 Jan; 35(1):e4621. PubMed ID: 34609036
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo Metabolic Profiles as Determined by
    Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
    Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
    Batsios G; Viswanath P; Subramani E; Najac C; Gillespie AM; Santos RD; Molloy AR; Pieper RO; Ronen SM
    Sci Rep; 2019 Jul; 9(1):10521. PubMed ID: 31324855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neurochemical Differences between 1p/19q Codeleted and Noncodeleted IDH-mutant Gliomas by in Vivo MR Spectroscopy.
    Branzoli F; Liserre R; Deelchand DK; Poliani PL; Bielle F; Nichelli L; Sanson M; Lehéricy S; Marjańska M
    Radiology; 2023 Sep; 308(3):e223255. PubMed ID: 37668523
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.
    Capper D; Simon M; Langhans CD; Okun JG; Tonn JC; Weller M; von Deimling A; Hartmann C;
    Int J Cancer; 2012 Aug; 131(3):766-8. PubMed ID: 21913188
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.
    Elkhaled A; Jalbert LE; Phillips JJ; Yoshihara HAI; Parvataneni R; Srinivasan R; Bourne G; Berger MS; Chang SM; Cha S; Nelson SJ
    Sci Transl Med; 2012 Jan; 4(116):116ra5. PubMed ID: 22238333
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.
    Andronesi OC; Arrillaga-Romany IC; Ly KI; Bogner W; Ratai EM; Reitz K; Iafrate AJ; Dietrich J; Gerstner ER; Chi AS; Rosen BR; Wen PY; Cahill DP; Batchelor TT
    Nat Commun; 2018 Apr; 9(1):1474. PubMed ID: 29662077
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.
    Molloy AR; Najac C; Viswanath P; Lakhani A; Subramani E; Batsios G; Radoul M; Gillespie AM; Pieper RO; Ronen SM
    Theranostics; 2020; 10(19):8757-8770. PubMed ID: 32754276
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma.
    Kalinina J; Carroll A; Wang L; Yu Q; Mancheno DE; Wu S; Liu F; Ahn J; He M; Mao H; Van Meir EG
    J Mol Med (Berl); 2012 Oct; 90(10):1161-1171. PubMed ID: 22426639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.